Total Payments
$18,054
2023 Payments
$17,240
Companies
6
Transactions
13
Medicare Patients
2,446
Medicare Billing
$201,287
Payment Breakdown by Category
Research$14,240 (78.9%)
Other$3,000 (16.6%)
Food & Beverage$814.40 (4.5%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $14,240 | 3 | 78.9% |
| Honoraria | $3,000 | 1 | 16.6% |
| Food and Beverage | $814.40 | 9 | 4.5% |
Payments by Type
Research
$14,240
3 transactions
General
$3,814
10 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ONQUALITY PHARMACEUTICALS (USA) LLC | $14,240 | 3 | $0 (2023) |
| Novocure Inc. | $3,000 | 1 | $0 (2023) |
| Genentech USA, Inc. | $261.62 | 2 | $0 (2018) |
| PFIZER INC. | $260.43 | 4 | $0 (2019) |
| AbbVie, Inc. | $167.55 | 2 | $0 (2019) |
| Novartis Pharmaceuticals Corporation | $124.80 | 1 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2023 | $17,240 | 4 | ONQUALITY PHARMACEUTICALS (USA) LLC ($14,240) |
| 2019 | $204.11 | 3 | PFIZER INC. ($148.51) |
| 2018 | $376.76 | 4 | Genentech USA, Inc. ($140.04) |
| 2017 | $233.53 | 2 | Genentech USA, Inc. ($121.58) |
All Payment Transactions
13 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/05/2023 | Novocure Inc. | — | Honoraria | Cash or cash equivalent | $3,000.00 | General |
| 06/28/2023 | ONQUALITY PHARMACEUTICALS (USA) LLC | — | — | Cash or cash equivalent | $469.98 | Research |
| Study: A Study to Investigate OQL011 on VEGFR Inhibitor-Associated Hand-Foot Skin Reaction in Cancer Patients (NOVA-II) | ||||||
| 05/12/2023 | ONQUALITY PHARMACEUTICALS (USA) LLC | — | — | Cash or cash equivalent | $9,540.00 | Research |
| Study: A Study to Investigate OQL011 on VEGFR Inhibitor-Associated Hand-Foot Skin Reaction in Cancer Patients (NOVA-II) | ||||||
| 04/26/2023 | ONQUALITY PHARMACEUTICALS (USA) LLC | — | — | Cash or cash equivalent | $4,229.82 | Research |
| Study: A Study to Investigate OQL011 on VEGFR Inhibitor-Associated Hand-Foot Skin Reaction in Cancer Patients (NOVA-II) | ||||||
| 06/26/2019 | AbbVie, Inc. | Skyrizi (Biological) | Food and Beverage | In-kind items and services | $55.60 | General |
| Category: Immunology | ||||||
| 01/17/2019 | PFIZER INC. | EUCRISA (Drug) | Food and Beverage | In-kind items and services | $121.09 | General |
| Category: DERMATOLOGY | ||||||
| 01/02/2019 | PFIZER INC. | — | Food and Beverage | In-kind items and services | $27.42 | General |
| 12/27/2018 | PFIZER INC. | — | Food and Beverage | In-kind items and services | $19.23 | General |
| 09/20/2018 | Genentech USA, Inc. | Erivedge (Biological) | Food and Beverage | In-kind items and services | $140.04 | General |
| Category: BioOncology | ||||||
| 05/23/2018 | Novartis Pharmaceuticals Corporation | COSENTYX (Biological) | Food and Beverage | In-kind items and services | $124.80 | General |
| Category: DERMATOLOGY | ||||||
| 03/08/2018 | PFIZER INC. | EUCRISA (Drug) | Food and Beverage | In-kind items and services | $92.69 | General |
| Category: DERMATOLOGY | ||||||
| 10/05/2017 | AbbVie, Inc. | Humira (Biological) | Food and Beverage | In-kind items and services | $111.95 | General |
| Category: Immunology | ||||||
| 02/22/2017 | Genentech USA, Inc. | Erivedge (Biological) | Food and Beverage | In-kind items and services | $121.58 | General |
| Category: BioOncology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A Study to Investigate OQL011 on VEGFR Inhibitor-Associated Hand-Foot Skin Reaction in Cancer Patients (NOVA-II) | ONQUALITY PHARMACEUTICALS (USA) LLC | $14,240 | 3 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 18 | 707 | 1,078 | $291,091 | $64,548 |
| 2022 | 15 | 551 | 806 | $180,172 | $43,174 |
| 2021 | 16 | 659 | 1,027 | $234,872 | $56,871 |
| 2020 | 12 | 529 | 853 | $161,613 | $36,695 |
Total Patients
2,446
Total Services
3,764
Medicare Billing
$201,287
Procedure Codes
61
All Medicare Procedures & Services
61 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 122 | 184 | $56,120 | $15,649 | 27.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 117 | 138 | $29,670 | $8,688 | 29.3% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 68 | 68 | $30,150 | $7,661 | 25.4% |
| 17110 | Destruction of skin growth, 1-14 growths | Office | 2023 | 64 | 71 | $28,045 | $5,328 | 19.0% |
| J7308 | Aminolevulinic acid hcl for topical administration, 20%, single unit dosage form (354 mg) | Office | 2023 | 12 | 18 | $21,175 | $5,293 | 25.0% |
| 12032 | Intermediate repair of wound of scalp, underarms, trunk, arms, or legs, 2.6-7.5 cm | Office | 2023 | 19 | 20 | $21,100 | $4,295 | 20.4% |
| 17000 | Destruction of precancer skin growth, 1 growth | Office | 2023 | 78 | 107 | $25,680 | $3,501 | 13.6% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 44 | 44 | $12,780 | $3,124 | 24.4% |
| 11102 | Biopsy of related skin growth, first growth | Office | 2023 | 37 | 41 | $14,555 | $2,478 | 17.0% |
| 11104 | Punch biopsy, first skin growth | Office | 2023 | 16 | 19 | $8,360 | $1,785 | 21.3% |
| 96567 | Application of light to destroy precancer skin growth | Office | 2023 | 12 | 16 | $8,080 | $1,327 | 16.4% |
| 96900 | Application of ultraviolet light to skin | Office | 2023 | 12 | 69 | $6,900 | $1,152 | 16.7% |
| 11301 | Shaving of skin growth of body, arms, or legs, 0.6-1.0 cm | Office | 2023 | 12 | 14 | $6,020 | $995.86 | 16.5% |
| 11602 | Removal of cancer skin growth of body, arms, or legs, 1.1-2.0 cm | Office | 2023 | 11 | 11 | $9,350 | $995.30 | 10.6% |
| 17003 | Destruction of precancer skin growth, 2-14 growths | Office | 2023 | 43 | 190 | $4,750 | $854.55 | 18.0% |
| 11900 | Injection into skin growth, 1-7 growths | Office | 2023 | 14 | 20 | $4,100 | $750.59 | 18.3% |
| 11300 | Shaving of skin growth of body, arms, or legs, 0.5 cm or less | Office | 2023 | 11 | 11 | $3,960 | $642.54 | 16.2% |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | Office | 2023 | 15 | 37 | $296.00 | $29.11 | 9.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 107 | 155 | $40,590 | $13,148 | 32.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 108 | 121 | $21,560 | $6,968 | 32.3% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 41 | 41 | $16,315 | $4,704 | 28.8% |
| 17110 | Destruction of skin growth, 1-14 growths | Office | 2022 | 48 | 58 | $21,380 | $3,870 | 18.1% |
| 12032 | Intermediate repair of wound of scalp, underarms, trunk, arms, or legs, 2.6-7.5 cm | Office | 2022 | 16 | 17 | $17,680 | $3,820 | 21.6% |
| 17000 | Destruction of precancer skin growth, 1 growth | Office | 2022 | 62 | 78 | $18,005 | $2,873 | 16.0% |
| 11102 | Biopsy of related skin growth, first growth | Office | 2022 | 30 | 34 | $11,535 | $1,987 | 17.2% |
About Dr. Brittany Dulmage, M.D
Dr. Brittany Dulmage, M.D is a Dermatology healthcare provider based in Westerville, Ohio. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/15/2015. The National Provider Identifier (NPI) number assigned to this provider is 1588050694.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Brittany Dulmage, M.D has received a total of $18,054 in payments from pharmaceutical and medical device companies, with $17,240 received in 2023. These payments were reported across 13 transactions from 6 companies. The most common payment nature is "" ($14,240).
As a Medicare-enrolled provider, Dulmage has provided services to 2,446 Medicare beneficiaries, totaling 3,764 services with total Medicare billing of $201,287. Data is available for 4 years (2020–2023), covering 61 distinct procedure/service records.
Ad
Practice Information
- Specialty Dermatology
- Location Westerville, OH
- Active Since 04/15/2015
- Last Updated 07/02/2024
- Taxonomy Code 207N00000X
- Entity Type Individual
- NPI Number 1588050694
Products in Payments
- Erivedge (Biological) $261.62
- EUCRISA (Drug) $213.78
- COSENTYX (Biological) $124.80
- Humira (Biological) $111.95
- Skyrizi (Biological) $55.60
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Dermatology Doctors in Westerville
Dr. Joshua Grosshandler, M.d, M.D
Dermatology — Payments: $378,447
Dermatology $378,447
Jess Demaria, Md, MD
Dermatology — Payments: $195,915
Dermatology $195,915
Rosina Lin, M.d, M.D
Dermatology — Payments: $17,300
Dermatology $17,300
Dr. Kevin Karikomi, D.o, D.O
Dermatology — Payments: $14,525
Dermatology $14,525
Jennifer Nash, M.d, M.D
Dermatology — Payments: $9,506
Dermatology $9,506
Sara Huff, Md, MD
Dermatology — Payments: $5,661
Dermatology $5,661